Precision NanoSystems is Now a Part of Danaher's Life Sciences Platform

Cytiva, Pall Corporation | June 02, 2021

Danaher Corporation's Life Sciences platform has acquired precision NanoSystems (PNI). PNI is a global leader in technologies and solutions for developing genetic medicines, including mRNA vaccines and therapeutics. PNI will join Danaher's Life Sciences platform and complement other businesses in the forum, including Cytiva and Pall.

"PNI has advanced several exciting innovations, and we're thrilled to welcome this talented team," says Emmanuel Ligner, Danaher Group Executive. "As mRNA has matured as a successful technology in some COVID vaccines, we see huge potential for this technology to accelerate other therapies. The work done thus far by the PNI team will also enable our customers at Cytiva and Pall to take a huge step forward in advancing their science to improve the lives of patients."

James Taylor, co-founder, and CEO of Precision NanoSystems, says: "Over the last ten years, PNI has been a leading technology company, enabling the development of genetic medicines. Joining Danaher's Life Sciences platform allows our world-class team to accelerate and expand the work we do to support our customers with comprehensive technology platforms and the expertise to manufacture transformative medicines for the benefit of humanity. With the global reach of the Danaher Life Sciences platform and customers who are leaders in biotechnology, this is an incredible opportunity to bring PNI's innovations to market and expand our impact."

The overall mRNA therapeutics and vaccines market was growing rapidly and accelerated with the development of COVID-19 mRNA vaccines. It is anticipated that mRNA technology will be used to develop other vaccines and to treat other conditions of high unmet medical need, such as cancer and genetic diseases.

At present, most mRNA therapies and other types of genetic medicines in clinical development are designed to be delivered with the help of lipid nanoparticles (LNPs). PNI's Genetic Medicine Toolkit, including its proprietary GenVoyTM LNP delivery platform and NanoAssemblrTM microfluidic-based nanoparticle manufacturing platform, enables the rapid development of genetic medicines. PNI's validated technologies increase the stability, efficacy, yield, and quality of non-viral genetic medication and lower the barrier to develop these essential medicines.

PNI is developing a new center of manufacturing excellence in Vancouver, which will proceed as planned. When complete, the biomanufacturing center will further advance Canadian therapeutic and vaccine manufacturing capabilities, broaden the domestic life sciences sector, create new jobs in the region, and foster a new generation of scientific talent.

About Pall
Pall Corporation may be a filtration, separation, and purification leader providing solutions to meet customers' critical fluid management needs across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety, and environmentally responsible technologies. The Company's engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide.

About Cytiva
Cytiva is a global life science leader with more than 8,000 associates across 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency, and capacity to research and manufacture workflows, enabling the development, manufacture, and delivery of transformative medicines to patients.


How the DNA got into the killer machine In a bacterium infected by T4, new bacteriophages are assembled in a stepwise process: the shaft builds up, DNA is replicated and the empty pro-head assembles as an empty shell. But how does the DNA get into the prohead?


How the DNA got into the killer machine In a bacterium infected by T4, new bacteriophages are assembled in a stepwise process: the shaft builds up, DNA is replicated and the empty pro-head assembles as an empty shell. But how does the DNA get into the prohead?

Related News


EXUMA Biotech Completes Series B2 to Advance Novel Cell & Gene Therapies

EXUMA Biotech Corp. | December 22, 2021

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, announced the completion of a $41 million Series B2 financing. The Series B2 brings the total capital raised since its inception to approximately $130 million. Proceeds will be used to support further development of EXUMA's autologous subcutaneous rPOC CAR-TaNK platform for hematologic and solid tumors and continued clinical investigation of its Tumor Metabolism Regulated CAR technology targeting solid tumors. New investors in the Series B2 financing included Americo Life, Inc., in addition to existing investors. "We are pleased to expand our investor base with support from this strategic group of investors who recognize the potential of our technologies to translate into life-changing therapies for cancer patients," Gregory Frost, Ph.D., EXUMA Biotech Chairman and Chief Executive Offer "Dr. Holmes is a renowned cancer specialist who will make an outstanding addition to our board of directors. He has dedicated his life to researching advanced cellular and immunotherapy treatments for hematologic malignancies and to the education of the oncology community about these new modalities," said Frost. Houston Holmes, M.D., received a BS in medical microbiology from Stanford University School of Medicine, an MD from the University of Texas Southwestern Medical School, and an MBA from the University of Texas at Dallas. He completed an internship and residency in internal medicine at Baylor University Medical Center, and fellowship in medical oncology/hematology at the National Cancer Institute/National Heart, Lung, and Blood Institute. Dr. Holmes has been in practice for over 20 years. "It's an exciting time for cell and gene therapies. I'm thrilled to be a part of EXUMA and to join the company in its mission to advance innovative therapies towards the clinic and for cancer patients in urgent need of new treatments," said Houston Holmes, M.D. About EXUMA Biotech EXUMA Biotech is a clinical-stage biotechnology company pioneering the discovery and development of novel cellular therapies and gene delivery solutions for patients with cancer. The company leverages its global R&D footprint to discover, manufacture and develop gene delivery platforms and gene programs that may overcome the safety, efficacy, and scalability challenges of cellular therapies in solid tumor and hematologic malignancies. The company is headquartered in West Palm Beach.

Read More


GT Molecular, Rapidly Expanding Molecular Diagnostics Biotech, Launches Two Highly Sensitive Tests for the Dangerous UK Variant of SARS-CoV-2

GT Molecular | January 13, 2021

GT Molecular, a quickly extending sub-atomic diagnostics biotech, has dispatched two profoundly delicate tests for the risky UK Variant of SARS-CoV-2 (B.1.1.7). These tale examines expand upon GT Molecular's clinical foundation and technology for profoundly exact and solid qPCR and advanced PCR recognition of SARS-CoV-2 virus and are offered in two formats. The fee-for-service testing of wastewater for the presence of SARS-CoV-2 and the variations available for use furnishes networks with a quick, exceptionally savvy technique to comprehend the measure of viral transmission inside a local area. Everybody inside a local area gives an example as a flush to the wastewater treatment office and a solitary wastewater test can cover a large number of individuals for a simple portion of what a clinical test for an individual expenses. Moreover, the presence of the infection in wastewater can go before nearby flare-ups locally by as long as seven days, giving wellbeing authorities time to prepare and increase testing. By applying this technique for local area wastewater checking to the recently coursing UK variation, GT Molecular is the first to go above and beyond and really "genotype the sewer".

Read More

Sartorius Stedim Biotech Closes Acquisition of Slovenian Purification Specialist BIA Separations

Sartorius | November 03, 2020

Sartorius Stedim Biotech (SSB), a leading partner of the biopharma industry, successfully closed the acquisition of the Slovenian purification specialist BIA Separations. The transaction was completed on November 2, 2020, after receiving the required approvals. "BIA's portfolio is highly complementary to Sartorius Stedim Biotech. We are thus creating an excellent offering for the manufacturing of gene therapies and other advanced therapies, and are pleased to welcome 120 new employees," said Dr. Joachim Kreuzburg, Chairman of the Board and CEO of Sartorius Stedim Biotech. The total purchase price of the transaction is 360 million euros of which 240 million euros were paid in cash and 120 million euros in SSB shares. Both parties have further agreed on three tranches of earn-out payments based on performance over the next five financial years. SSB has been preparing to integrate BIA Separations so this can now be initiated despite the special conditions prevailing during the pandemic. BIA Separations develops and manufactures market-leading products for purification and analysis of large biomolecules, such as viruses, plasmids and mRNA, which are used in cell and gene therapies and other advanced therapies. BIA's technology for manufacturing-scale purification is already used in production of the first commercialized advanced therapeutics, and the company also has a strong presence with such novel drug candidates in the clinical pipeline. Expecting continued very strong double-digit sales growth over the next few years, BIA is forecasted to earn sales revenue of approx. 25 million euros in 2020 at profit margins that will be accretive to the underlying EBITDA margin of the Sartorius Stedim Biotech Group. The transaction is not expected to have any material impact on Sartorius Stedim Biotech's 2020 results.

Read More